147 related articles for article (PubMed ID: 21909080)
1. CXCR4 expression correlates with the degree of tumor infiltration and BRAF status in papillary thyroid carcinomas.
Torregrossa L; Giannini R; Borrelli N; Sensi E; Melillo RM; Leocata P; Materazzi G; Miccoli P; Santoro M; Basolo F
Mod Pathol; 2012 Jan; 25(1):46-55. PubMed ID: 21909080
[TBL] [Abstract][Full Text] [Related]
2. E-selectin expression and BRAF status in papillary thyroid carcinomas: Correlation with clinicopathologic features.
Miccoli P; Torregrossa L; Borrelli N; Materazzi G; Cacciato Insilla A; Miccoli M; Basolo F
Surgery; 2014 Dec; 156(6):1550-7; discussion 1557-8. PubMed ID: 25456953
[TBL] [Abstract][Full Text] [Related]
3. Epidermal growth factor receptor overexpression is a marker for adverse pathologic features in papillary thyroid carcinoma.
Fisher KE; Jani JC; Fisher SB; Foulks C; Hill CE; Weber CJ; Cohen C; Sharma J
J Surg Res; 2013 Nov; 185(1):217-24. PubMed ID: 23746767
[TBL] [Abstract][Full Text] [Related]
4. Role and relevance of BRAF mutations in risk stratifying patients of papillary thyroid cancers along with a review of literature.
Krishnamurthy A; Ramshankar V; Murherkar K; Vidyarani S; Raghunandhan GC; Das A; Desai PB; Albert K
Indian J Cancer; 2017; 54(1):372-378. PubMed ID: 29199726
[TBL] [Abstract][Full Text] [Related]
5. Molecular correlates and rate of lymph node metastasis of non-invasive follicular thyroid neoplasm with papillary-like nuclear features and invasive follicular variant papillary thyroid carcinoma: the impact of rigid criteria to distinguish non-invasive follicular thyroid neoplasm with papillary-like nuclear features.
Cho U; Mete O; Kim MH; Bae JS; Jung CK
Mod Pathol; 2017 Jun; 30(6):810-825. PubMed ID: 28281551
[TBL] [Abstract][Full Text] [Related]
6. Immunohistochemistry is highly sensitive and specific for detecting the BRAF V600E mutation in papillary thyroid carcinoma.
Sun J; Zhang J; Lu J; Gao J; Lu T; Ren X; Duan H; Liang Z
Int J Clin Exp Pathol; 2015; 8(11):15072-8. PubMed ID: 26823846
[TBL] [Abstract][Full Text] [Related]
7. Study of peripheral BRAF(V600E) mutation as a possible novel marker for papillary thyroid carcinomas.
Kwak JY; Jeong JJ; Kang SW; Park S; Choi JR; Park SJ; Kim EK; Chung WY
Head Neck; 2013 Nov; 35(11):1630-3. PubMed ID: 23161556
[TBL] [Abstract][Full Text] [Related]
8. Uncommon BRAF mutations in the follicular variant of thyroid papillary carcinoma: New insights.
Rossi ED; Martini M; Bizzarro T; Capodimonti S; Cenci T; Lombardi CP; Pontecorvi A; Fadda G; Larocca LM
Cancer Cytopathol; 2015 Oct; 123(10):593-602. PubMed ID: 26230187
[TBL] [Abstract][Full Text] [Related]
9. Classic Architecture with Multicentricity and Local Recurrence, and Absence of TERT Promoter Mutations are Correlates of BRAF (V600E) Harboring Pediatric Papillary Thyroid Carcinomas.
Onder S; Ozturk Sari S; Yegen G; Sormaz IC; Yilmaz I; Poyrazoglu S; Sanlı Y; Giles Senyurek Y; Kapran Y; Mete O
Endocr Pathol; 2016 Jun; 27(2):153-61. PubMed ID: 26951110
[TBL] [Abstract][Full Text] [Related]
10. Lack of association of BRAF mutation with negative prognostic indicators in papillary thyroid carcinoma: the University of California, San Francisco, experience.
Gouveia C; Can NT; Bostrom A; Grenert JP; van Zante A; Orloff LA
JAMA Otolaryngol Head Neck Surg; 2013 Nov; 139(11):1164-70. PubMed ID: 24030686
[TBL] [Abstract][Full Text] [Related]
11. BRAF V600E mutation is associated with tumor aggressiveness in papillary thyroid cancer.
Kim SJ; Lee KE; Myong JP; Park JH; Jeon YK; Min HS; Park SY; Jung KC; Koo do H; Youn YK
World J Surg; 2012 Feb; 36(2):310-7. PubMed ID: 22190222
[TBL] [Abstract][Full Text] [Related]
12. Prognostic prediction of BRAF(V600E) and its relationship with sodium iodide symporter in classic variant of papillary thyroid carcinomas.
Gao WL; Wie LL; Chao YG; Wie L; Song TL
Clin Lab; 2012; 58(9-10):919-26. PubMed ID: 23163107
[TBL] [Abstract][Full Text] [Related]
13. Combined effect of Hashimoto's thyroiditis and BRAF(V600E) mutation status on aggressiveness in papillary thyroid cancer.
Kim SJ; Myong JP; Jee HG; Chai YJ; Choi JY; Min HS; Lee KE; Youn YK
Head Neck; 2016 Jan; 38(1):95-101. PubMed ID: 25213729
[TBL] [Abstract][Full Text] [Related]
14. Well-differentiated thyroid cancer with a minor poorly differentiated component: clonal heterogeneity through the prognostic role of CXCR4 and BRAF analysis.
Rossi ED; Martini M; Capodimonti S; Straccia P; Revelli L; Lombardi CP; Pontecorvi A; Santeusanio G; Larocca LM; Fadda G
Appl Immunohistochem Mol Morphol; 2015 Mar; 23(3):196-201. PubMed ID: 24992171
[TBL] [Abstract][Full Text] [Related]
15. Clinicopathologic correlations of the BRAFV600E mutation, BRAF V600E immunohistochemistry, and BRAF RNA in situ hybridization in papillary thyroid carcinoma.
Jung YY; Yoo JH; Park ES; Kim MK; Lee TJ; Cho BY; Chung YJ; Kang KH; Ahn HY; Kim HS
Pathol Res Pract; 2015 Feb; 211(2):162-70. PubMed ID: 25468810
[TBL] [Abstract][Full Text] [Related]
16. Clinical significance of BRAF mutation in thyroid papillary cancer.
Fernandez IJ; Piccin O; Sciascia S; Cavicchi O; Repaci A; Vicennati V; Fiorentino M
Otolaryngol Head Neck Surg; 2013 Jun; 148(6):919-25. PubMed ID: 23482475
[TBL] [Abstract][Full Text] [Related]
17. Occult oncocytic papillary thyroid carcinoma with lymphoid stroma (Warthin-like tumor): report of a case with concomitant mutations of BRAF V600E and V600K.
Han F; Zhang L; Zhang S; Zhou H; Yi X
Int J Clin Exp Pathol; 2015; 8(5):5896-901. PubMed ID: 26191315
[TBL] [Abstract][Full Text] [Related]
18. A comparison of the clinicopathological features and prognoses of the classical and the tall cell variant of papillary thyroid cancer: a meta-analysis.
Liu Z; Zeng W; Chen T; Guo Y; Zhang C; Liu C; Huang T
Oncotarget; 2017 Jan; 8(4):6222-6232. PubMed ID: 28009980
[TBL] [Abstract][Full Text] [Related]
19. The role of BRAF(V600E) mutation as poor prognostic factor for the outcome of patients with intrathyroid papillary thyroid carcinoma.
Pelizzo MR; Dobrinja C; Casal Ide E; Zane M; Lora O; Toniato A; Mian C; Barollo S; Izuzquiza M; Guerrini J; De Manzini N; Merante Boschin I; Rubello D
Biomed Pharmacother; 2014 May; 68(4):413-7. PubMed ID: 24721322
[TBL] [Abstract][Full Text] [Related]
20. Thyroid Papillary Microtumor: Validation of the (Updated) Porto Proposal Assessing Sex Hormone Receptor Expression and Mutational BRAF Gene Status.
Aliyev E; Ladra-González MJ; Sánchez-Ares M; Abdulkader-Nallib I; Piso-Neira M; Rodríguez-Carnero G; Vieiro-Balo P; Pérez-Becerra R; Gude-Sampedro F; Barreiro-Morandeira F; Alvarez CV; Cameselle-Teijeiro JM
Am J Surg Pathol; 2020 Sep; 44(9):1161-1172. PubMed ID: 32804453
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
